Market Access Intelligence Infrastructure powering investors, innovators, and institutions
AI-augmented intelligence infrastructure built on 40+ years of market access expertise
THE INVISIBLE BARRIER TO LIFE SCIENCES INNOVATION
Despite substantial investment in research and development, a significant portion of promising life sciences innovations fail to reach patients—not due to safety or efficacy concerns, but because of market access complexity.
Market access intelligence—understanding how life sciences innovations get covered, reimbursed, and adopted—remains one of the most fragmented knowledge domains in the life sciences ecosystem. This fragmentation creates a systemic barrier to innovation with cascading consequences across the entire industry.
-
Make investment decisions with complete information
You're evaluating a breakthrough therapy. The science works. But will payers cover it? Due diligence delivers insights that expire in months as policies change. Portfolio companies keep asking the same market access questions you can't answer systematically. Each deal starts from scratch, and capital flows to innovations with unclear paths to reimbursement while viable opportunities stay underfunded.
-
Make strategic plans with complete visibility
Companies design clinical trials without knowing if payers will value their endpoints. They choose indications without systematic reimbursement intelligence. They plan market launches while coverage policies shift quarterly. The expertise to navigate this landscape is difficult to hire and expensive to consult. Most companies discover their market access challenges after millions are spent, when pivoting becomes prohibitively expensive.
-
Connect fragmented knowledge across stakeholders
Investment insights from one portfolio company could inform strategic decisions at another. Coverage intelligence generated through regulatory work has value for M&A evaluation. Consultant expertise gained on international projects applies to the US market entry. But this knowledge stays siloed. Each stakeholder reinvents analysis that already exists elsewhere in the ecosystem, multiplying effort and cost across the industry.
CROSS-STAKEHOLDER INTELLIGENCE REMAINS DISCONNECTED
Investment decisions, strategic planning, M&A activities, coverage evaluations, and policy development all require market access intelligence, yet these stakeholders rarely benefit from shared learning. Knowledge generated in one context has value across the ecosystem, but infrastructure to enable this exchange doesn't exist.
What’s needed is intelligence infrastructure
Built to serve diverse stakeholders simultaneously, designed for integration into existing workflows, and architected to compound in value as more participants contribute to and benefit from shared intelligence. Infrastructure that democratizes market access knowledge the same way financial data infrastructure democratized investment intelligence.
The opportunity isn't building another point solution. It's creating the foundational intelligence layer that the entire life sciences ecosystem currently lacks.